Is this your company? Claim your profile to update info and connect with investors.
Claim profile

TEM · Stock Price

USD 53.50-11.72 (-17.97%)
Market Cap: $9.2B

Historical price data

Market Cap: $9.2BPipeline: 7 drugsPatents: 13Employees: 1000-5000HQ: Chicago, United States

Overview

Tempus AI is a public technology company with a mission to enable data-driven, personalized medicine through its proprietary AI platform and massive, structured real-world data library. Its core strategy involves a virtuous cycle: generating revenue through clinical testing and data/analytics services for providers and life sciences companies, while using that same data flow to fuel internal therapeutic discovery and enhance its platform's predictive power. Key achievements include establishing a dominant data network with over 65% of U.S. academic medical centers, securing multiple FDA clearances for its diagnostic assays, building a pipeline of seven internal drug candidates, and being selected for strategic government partnerships like the ARPA-H ADAPT program.

OncologyCardiologyNeurologyPsychiatryInfectious Disease

Technology Platform

An integrated AI-powered operating system that aggregates, structures, and analyzes multimodal clinical and molecular data (genomics, pathology, radiology, clinical notes) to generate insights for clinical decision support, drug development, and therapeutic discovery.

Pipeline

7
7 drugs in pipeline
DrugIndicationStageWatch
Pegylated interferon alpha 2 + RibavirinHepatitis CApproved
Pegylated IFN- alpha 2b + RibavirinHepatitis CApproved
Targeted Therapy Based on Molecular Profiling + Standard-of-...Metastatic Malignant NeoplasmPhase 2
NiraparibSolid TumorPhase 2
A2B694 + A2B543Solid Tumor, AdultPhase 1/2

Funding History

4
Total raised:$1.0B
IPO$410M
Series I$200M
Series H$200M
Series G$200M

Company Timeline

2024IPO

IPO — $410.0M

2024Series I

Series I: $200.0M

2024Series H

Series H: $200.0M